Demographic trends towards an aging population, soaring diagnosis rates in diabetes, obesity and cardiovascular disease are just a few of the factors that are driving growth and spurring innovation to better serve millions of wound care patients each year.  The wound care industry has many verticals for sales, but probably none more critical than diabetic foot ulcers.  Diabetic foot ulcers affect about 15 percent of the nearly 26 million people with diabetes in the United States, and Read More

Cardium Therapeutics Ltd. (NYSE MKT: CXM), an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and business with the potential to address significant unmet medical needs and definable pathways to commercialization, similar to companies like Impax Laboratories Inc. (NASDAQ: IPXL) and Osiris Therapeutics Inc. (NASDAQ: OSIR), said today that they have assembled a new Excellagen Medical Advisory Board as part of corporate initiatives Read More

Christopher J. Reinhard, Chairman & CEO presented at the Marcum MicroCap Conference on June 20, 2012 at at the Roosevelt Hotel in New York City. In the presentation, Mr. Reinhard details Cardium products, including Generx as a product candidate for advanced coronary artery disease, Excellagen for wound care management and the company’s line of MedPodium neutraceuticals,metabolics and aesthetics. Read More

Cardium Announces Plans For Commercializaton Of Excellagen® In The Russian Federation

Cardium Therapeutics (NYSE MKT: CXM) announced an agreement with Advanced Biosciences Research, an affiliate of bioRASI, for the planned commercialization of Cardium’s professional-use Excellagen® topical wound care management product in Russia and the nine additional member countries comprising the Commonwealth of Independent States (CIS).  Under this agreement, bioRASI will be responsible for Read More

AMRI Burlington Contracted As Aseptic Fill Manufacturer for Market Introduction of Excellagen® Wound Care Product

AMRI (NASDAQ: AMRI) announced today that its Burlington site was contracted by Cardium Therapeutics (NYSE MKT: CXM) and its subsidiary, Tissue Repair Company (“Cardium”) to manufacture sterile pre-filled syringes in support of the U.S. introduction of Excellagen®, a professional-use, formulated collagen-based product for the management of diabetic foot ulcers, pressure ulcers and other dermal wounds. AMRI’s highly collaborative approach to technical transfer enabled Cardium to meet its commercial introduction timeline and overall business needs. Read More

Cardium Therapeutics (AMEX: CXM), health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, similar to companies like Impax Laboratories Inc. (Nasdaq: IPXL) and Biogen Idec Inc. (Nasdaq: BIIB), recently launched Excellagen™ into the U.S. marketplace in a move that could unlock significant value for shareholders. Read More